A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study

Abstract Background Patients with chronic lung disease (CLD) and post-COVID syndrome suffer from multidimensional impairment that is often incompletely addressed by pharmacotherapy alone. We evaluated a ward-based multidisciplinary pathway integrating pharmacotherapy, psychological support, and pulmonary rehabilitation. Methods In this prospective controlled cohort study, 360 hospitalized patients with CLD and post-COVID syndrome received integrated multidisciplinary care ( n = 120) or usual care ( n = 240). The primary outcomes were changes in PaCO₂, FEV₁% predicted, and CT-assessed residual radiological abnormality extent. Patient-reported outcomes, functional capacity, inflammation, and 6-month follow-up data were also assessed. Analyses used adjusted regression and IPTW. Results Integrated care was associated with greater improvements in the three primary outcomes: PaCO₂, adjusted β − 0.98 mmHg (95% CI − 1.21 to − 0.75; P < 0.001); FEV₁% predicted, adjusted β 2.35% points (95% CI 1.53 to 3.17; P < 0.001); and CT-assessed residual abnormality extent, adjusted β − 0.55% points (95% CI − 0.87 to − 0.24; P < 0.001). Integrated care was also associated with greater improvements in SGRQ score, SAS score, 15-minute walking distance, CRP, ESR, and sleep-quality score. The composite early clinical benefit rate was higher in the integrated-care group than in the usual-care group, with an adjusted OR of 1.91 (95% CI 1.21 to 3.01; P = 0.006). At 6 months, sleep quality was better and symptom-related medication use was lower, while rehospitalisation, acute exacerbation, and CT progression rates were similar between groups. Conclusions The integrated pathway was associated with broader short-term clinical improvement and lower symptom-related treatment burden at follow-up, although rehospitalisation, acute exacerbation, and CT progression rates were similar between groups.

Authors

Institutions

Publication Details

Journal
Egyptian Journal of Bronchology
Published
2026-05-23
DOI
https://doi.org/10.1186/s43168-026-00587-3
Primary Topic
Long-Term Effects of COVID-19
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study

Juan Pen, Shengjun Ma, Kai Sun, Aibo Zheng et al.
Egyptian Journal of Bronchology
Long-Term Effects of COVID-19
article

A multidisciplinary pulmonary rehabilitation pathway for hospitalized patients with chronic lung disease and post-COVID syndrome: a prospective controlled cohort study

Juan Pen, Shengjun Ma, Kai Sun, Aibo Zheng, Wenjun Li, Zhiyu Chen, Xin Ming, Yan Jin, Feizhong Gong
article en

Abstract

Abstract Background Patients with chronic lung disease (CLD) and post-COVID syndrome suffer from multidimensional impairment that is often incompletely addressed by pharmacotherapy alone. We evaluated a ward-based multidisciplinary pathway integrating pharmacotherapy, psychological support, and pulmonary rehabilitation. Methods In this prospective controlled cohort study, 360 hospitalized patients with CLD and post-COVID syndrome received integrated multidisciplinary care ( n = 120) or usual care ( n = 240). The primary outcomes were changes in PaCO₂, FEV₁% predicted, and CT-assessed residual radiological abnormality extent. Patient-reported outcomes, functional capacity, inflammation, and 6-month follow-up data were also assessed. Analyses used adjusted regression and IPTW. Results Integrated care was associated with greater improvements in the three primary outcomes: PaCO₂, adjusted β − 0.98 mmHg (95% CI − 1.21 to − 0.75; P < 0.001); FEV₁% predicted, adjusted β 2.35% points (95% CI 1.53 to 3.17; P < 0.001); and CT-assessed residual abnormality extent, adjusted β − 0.55% points (95% CI − 0.87 to − 0.24; P < 0.001). Integrated care was also associated with greater improvements in SGRQ score, SAS score, 15-minute walking distance, CRP, ESR, and sleep-quality score. The composite early clinical benefit rate was higher in the integrated-care group than in the usual-care group, with an adjusted OR of 1.91 (95% CI 1.21 to 3.01; P = 0.006). At 6 months, sleep quality was better and symptom-related medication use was lower, while rehospitalisation, acute exacerbation, and CT progression rates were similar between groups. Conclusions The integrated pathway was associated with broader short-term clinical improvement and lower symptom-related treatment burden at follow-up, although rehospitalisation, acute exacerbation, and CT progression rates were similar between groups.

Egyptian Journal of BronchologyVol. 20(1)
Zigong First People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 5%
Long-Term Effects of COVID-19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.